Association of Maternal Mild Hypothyroidism With Offspring Neurodevelopment in TPOAb-Negative Women: A Prospective Cohort Study

Qingru Wang1, Yangqian Jiang1,2, Hong Lv1,2,3, Qun Lu1,2, Shiyao Tao1,2, Rui Qin1,2, Lei Huang1,2, Cong Liu1,2, Xin Xu1,2, Siyuan Lv1,4, Mei Li1,5, Zhi Li1,5, Jiangbo Du1,2,3, Yuan Lin1,3,6, Hongxia Ma1,2,3, Xin Xu1,2, Siyuan Lv1,4, Mei Li1,5, Zhi Li1,5, Jiangbo Du1,2,3, Tao Jiang8* and Guoying Zhang1,9*

1 State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China, 2 Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China, 3 State Key Laboratory of Reproductive Medicine (Suzhou Centre), The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China, 4 Department of Toxicology and Nutritional Science, School of Public Health, Nanjing Medical University, Nanjing, China, 5 Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China, 6 Department of Maternal, Child and Adolescent Health, School of Public Health, Nanjing Medical University, Nanjing, China, 7 Department of Child Health Care, Women’s Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China, 8 Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China, 9 Department of Obstetrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing, China

Objectives: Adequate maternal thyroid hormone availability is crucial for fetal neurodevelopment, but the role of maternal mild hypothyroidism is not clear. We aim to investigate the association of maternal mild hypothyroidism with neurodevelopment in infants at 1 year of age among TPOAb-negative women.

Methods: The present study was conducted within the Jiangsu Birth Cohort. A total of 793 mother–infant pairs were eligible for the present study. Maternal thyroid function was assessed by measuring serum thyroid-stimulating hormone, free thyroxine, and thyroid peroxidase antibodies. Neurodevelopment of infants was assessed by using the Bayley Scales of Infant and Toddler Development third edition screening test (Bayley-III screening test).

Results: In the multivariate adjusted linear regression analyses, infants of women with subclinical hypothyroidism and isolated hypothyroxinemia were associated with decreased receptive communication scores ($\beta = -0.68, p = 0.034$) and decreased gross motor scores ($\beta = -0.83, p = 0.008$), respectively. Moreover, infants of women with high-normal TSH concentrations (3.0–4.0 mIU/L) and low FT4 concentrations were significantly associated with lower gross motor scores ($\beta = -1.19, p = 0.032$), while no differences were observed in infants when the mothers had a high-normal TSH concentration and normal FT4 levels.

Citation: Wang Q, Jiang Y, Lv H, Lu Q, Qin R, Huang L, Liu C, Xu X, Lv S, Li M, Li J, Lin Y, Ma H, Chi X, Hu Z, Jiang T and Zhang G (2022) Association of Maternal Mild Hypothyroidism With Offspring Neurodevelopment in TPOAb-Negative Women: A Prospective Cohort Study. Front. Endocrinol. 13:884851. doi: 10.3389/fendo.2022.884851
INTRODUCTION

Maternal mild hypothyroidism is a common endocrine condition and occurs in 5%–18% of all pregnancies, depending on the definition used and population studied (1–3). Thyroid hormone is essential for optimum neurodevelopment of the fetus, acting on various stages of fetal neurological development, including neuronal migration, synaptogenesis, glial cell proliferation, and glial cell myelination (4, 5). Because the fetal thyroid gland is not functional until mid-gestation, the fetus predominantly depends on the supply of maternal thyroid hormone during that period (6). Therefore, maternal mild hypothyroidism may impair the neurodevelopment in offspring.

Results from animal studies have shown that shortage of thyroid hormone is associated with impaired brain development (7). Data from a large case–control study have demonstrated reduced scores on tests of intelligence, attention, and visual–motor performance at 8 years of age among children of mothers with untreated overt hypothyroidism (OH) during pregnancy compared to euthyroid controls (8, 9). Evidence from observational studies has demonstrated that maternal isolated hypothyroxinemia (IH) is predominantly associated with various types of neurodevelopmental disorders in children (10–12). However, the detrimental effects of maternal subclinical hypothyroidism (SCH) on fetal neurodevelopment remain less well established. Some studies have demonstrated that the offspring of women with SCH have decreased intelligence and motor ability or increased risk for delay in neurodevelopment (13–15), whereas others have shown conflicting results (10, 16, 17). This variation may be attributed to the different criteria for elevated thyroid-stimulating hormone (TSH) used in different studies (18).

Previous international guidelines have recommended using fixed upper limits of 2.5 mIU/L for the first trimester and 3.0 mIU/L for the second and third trimesters (1–3). Because studies have demonstrated that using these fixed upper limits in the 2011 guidelines results in overdiagnosis of SCH (19–22), the upper limit of TSH at 4.0 mIU/L for each trimester of pregnancy was advocated by the American Thyroid Association (ATA) 2017 guidelines (18). Moreover, only a few studies have investigated infant neurodevelopment among women with TSH concentrations between 3.0 and 4.0 mIU/L. Thus, the present study aimed to examine the association of maternal mild hypothyroidism with infant neurodevelopment, especially in women with high-normal TSH concentrations (3.0–4.0 mIU/L).

Conclusions: Maternal subclinical hypothyroidism is associated with decreased receptive communication scores in infants at 1 year of age. In addition, maternal TSH concentration greater than 4.0 mIU/L and maternal isolated hypothyroxinemia are associated with impaired gross motor ability of infants, especially in infants of women with high-normal TSH concentrations (3.0–4.0 mIU/L).

Keywords: thyroid hypofunction, pregnancy, neurodevelopment, infancy, cohort study

METHODS

Study Design and Participants

This cohort study was embedded in the Jiangsu Birth Cohort (JBC), a population-based prospective and longitudinal study recruiting women who planned to receive assisted reproductive technology (ART) and who are at their first trimester of spontaneous pregnancy (SP) at clinics in Jiangsu, China (23). When infants reached 1 year of age, they were invited to hospitals for systematic medical examination. The present study included the mother–infant pairs if the maternal TSH, free thyroxine (FT4), and thyroid peroxidase antibody (TPOAb) had been measured during pregnancy. Only mother–infant pairs with infants who had neurodevelopment data at the age of 1 year were included. We excluded pairs if the mother had a pre-existing thyroid disorder, if the mother had treatment for a thyroid disorder or the maternal TPOAb was positive, and we further exclude pairs if the mother had elevated concentrations of FT4 or suppressed TSH. The detailed cohort design and data collection have been previously published (23). This study was approved by the institutional review board of Nanjing Medical University, China NJMUIRB (2017) 002. Written informed consent was obtained from all the participants or the infants’ parents or guardians.

The participants were divided into four groups according to maternal thyroid hormone levels as follows: euthyroidism (ET, normal concentration of TSH and FT4), overt hypothyroidism (OH, elevated concentration of TSH with low concentration of FT4), subclinical hypothyroidism (SCH, elevated concentration of TSH with normal concentration of FT4), and isolated hypothyroxinemia (IH, normal concentration of TSH and low concentration of FT4).

Maternal Thyroid Parameters

Measures of thyroid functions including TSH, FT4, and TPOAb, were evaluated by electro-chemiluminescent microparticle immunoassays kits using the Architect system (Roche GmbH, Mannheim, Germany) in the Department of Clinical Laboratory in the Nanjing Maternity and Child Health Care Hospital. The intra-assay coefficients of variations were as follows: TSH < 5.3% and FT4 < 5.3%. The normal range for TSH was 0.2–4.0 mIU/L according to the ATA 2017 guidelines (18). The specific reference intervals (95% CI: 10.55–17.21 pmol/L) of FT4 for the study population were obtained according to the National Institute of Clinical Biochemistry (NACB) (24). TPOAb was considered positive at concentrations greater than 34 IU/ml.
Assessment of Neurodevelopment

When infants reached approximately 1 year of age, their neurodevelopment was assessed with the Bayley Scales of Infant and Toddler Development third edition screening test (Bayley-III screening test) by standardized trained pediatricians or occupational therapists in the presence of a primary caregiver (25). This test uses a subset of items from the full-length Bayley-III Scales, which has been widely validated and extensively used to compare developmental outcomes across individuals worldwide (25). Following standard procedures, we administered the following five subscales of the Bayley-III screen test: cognition, receptive language, expressive language, fine motor, and gross motor. Each subscale consisted of a series of developmental play tasks, and the subscale-specific raw scores of completed items were then recorded.

In the present study, a series of approaches was adopted to ensure the validity and reliability of the infant neurodevelopmental evaluation. The evaluation environment was quiet and non-interfering. One developmental neuropsychologist was appointed to provide professional training of the standardized administration before the investigation. Additionally, with the informed consent of guardians, the entire assessments of all examiners were filmed, and some of the videos were randomly selected for secondary evaluation monthly. The pediatricians and occupational therapists who performed the tests were unaware of any other test outcomes, including maternal thyroid hormone levels during pregnancy.

Covariates

Detailed information was obtained through questionnaires administered by trained interviews and comprised information on maternal and infant demographics, pregnancy-related information, and medical history. The covariates were chosen based on what was available within the data and following the literature review (18, 23). Potential confounding variables accounted for in the study were childbearing age (years) (26), maternal pre-pregnancy BMI (kg/m²) (27), parity (nulliparous/multiparous) (28), maternal education (<12≥12 years) (29), mode of conception(spontaneous/ART) (30), diseases during pregnancy (diabetes/non-diabetes, and hypertension/non-hypertension) (31, 32), gestational age (33), and infant sex (male/female) (34).

Statistical Analyses

Continuous variables with a normal distribution were expressed as mean (standard deviation, SD) and compared using Student’s t-test. Non-normally distributed variables were expressed as median (interquartile range, IQR) and compared using the Wilcoxon rank test. Categorical variables were expressed as percentage (%) and compared by the chi-squared test. Non-response analyses were performed to compare with the characteristics of the mother–infant pairs grouped by neurodevelopment assessment data availability according to different thyroid function groups.

Multivariate linear regression models were constructed to estimate the associations of maternal SCH, IH, and OH with offspring neurodevelopment. We developed a directed acyclic graph (DAG; Figure S1) to document our assumptions about the association between the covariates, exposure, and outcome, and specifically to hypothesize which variables were confounders (preceding both exposure and outcome). The casual directed acyclic graphs (DAGs) is a useful tool for researchers to understand the potential interplay among variables and to deduce which variables require control to minimize bias and which variables could introduce bias if controlled in the analysis (35). This DAG informed our staged modeling approach: model 1 was crude (unadjusted) and model 2 was adjusted for confounders (childbearing age, pre-pregnancy BMI, parity, maternal education level, mode of conception, and sex of infants). Gestational age at birth and diseases during pregnancy were considered potential intermediates and not included in the main model.

RESULTS

From December 2018 to September 2020, a total of 1,693 singleton infants born in Nanjing Maternal and Child Health Hospital had reached 1 year old. Data on TSH, FT4 and TPOAb were obtained for 1,533 mothers. In total, 178 mother–infant pairs were excluded because they met exclusion criteria, and 562 mother–infant pairs were excluded because the infants did not have neurodevelopment assessment at the age of 1 year. Thus, the final study population was composed of 793 mother–infant pairs. Of these 793 mother–infant pairs, 4.92% of the women...
were identified as SCH, 3.65% of the women were identified as IH, and only 0.38% of the women were identified as OH according to the 2017 ATA guidelines; 2.52% (20/793) of the women who had elevated concentrations of FT4 or suppressed TSH were excluded (Figure 2). The remaining 773 pairs had 1.0%, 1.3%, 1.3%, and 2.2% missing values of pre-pregnancy BMI, drinking during pregnancy, maternal education, and duration of breastfeeding.

TABLE 1 | Characteristics of mother–infant pairs.

| Characteristics | ET (n = 702) | SCH (n = 39) | IH (n = 29) | OH (n = 3) |
|-----------------|-------------|-------------|-------------|-------------|
| TSH (mIU/L)     | 2.01 (1.43–2.60) | 4.72 (4.26–6.45)** | 2.07 (1.47–3.31) | 5.48 (4.86–6.77)** |
| FT4 (pmol/L)    | 13.34 (12.30–14.40) | 12.42 (11.81–13.94)* | 10.15 (9.68–10.35)** | 9.58 (9.54–10.01)** |
| Gestational age at blood sampling (weeks) | 23.87 (0.67) | 23.85 (0.50) | 24.04 (0.56) | 23.76 (0.59) |
| Childbearing age (years) | 30.64 (3.89) | 29.83 (4.49) | 33.14 (4.00)** | 31.40 (2.11) |
| Pre-pregnancy BMI (kg/m²), n (%) | 21.63 (2.92) | 20.79 (2.63) | 22.94 (2.91)* | 22.30 (3.55) |
| <18.5 | 76 (10.8) | 7 (17.9) | 1 (3.4) | 0 (0.0) |
| 18.5–23.9 | 487 (69.4) | 24 (61.5) | 17 (56.8) | 2 (66.7) |
| 24–27.9 | 110 (15.7) | 6 (15.4) | 10 (34.5) | 1 (33.3) |
| ≥28 | 23 (3.3) | 0 (0.0) | 1 (3.4) | 0 (0.0) |
| Missing | 6 (0.8) | 2 (5.1) | 0 (0.0) | 0 (0.0) |
| Spontaneous conception, n (%) | 559 (79.6) | 30 (76.9) | 17 (58.6)* | 1 (33.3) |
| Primiparous, n (%) | 546 (77.8) | 30 (76.9) | 21 (79.3) | 3 (100.0) |
| Smoking during pregnancy, n (%) | 0 (0.0) | 0 (0.0) | 1 (3.4)* | 0 (0.0) |
| Drinking during pregnancy, n (%) | 4 (0.6) | 2 (5.1)* | 0 (0.0) | 0 (0.0) |
| Yes | 10 (1.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Maternal education (years), n (%) | 614 (87.5) | 30 (76.9) | 20 (69.0)* | 3 (100.0) |
| >12 | 9 (1.3) | 0 (0.0) | 1 (3.4) | 0 (0.0) |
| Missing | 191 (27.2) | 6 (15.4) | 13 (44.8) | 3 (100.0)* |
| Diseases during pregnancy* | 41 (5.8) | 1 (2.6) | 4 (13.8) | 0 (0.0) |
| Diabetes, n (%) | 384 (54.7) | 23 (59.0) | 9 (31) | 1 (33.3) |
| Hypertension, n (%) | 340 (48.4) | 23 (59.0) | 13 (44.8) | 1 (33.3) |
| Infant sex (male), n (%) | 3,411 (456) | 3,407 (343) | 3,365 (421) | 4,107 (189)* |
| Birthweight (g) | 39.46 (1.34) | 39.72 (1.13) | 39.26 (1.20) | 39.48 (0.21) |
| Gestational age (weeks) | 27 (3.8) | 1 (2.6) | 1 (3.4) | 0 (0.0) |
| Duration of breastfeeding (months), n (%) | 423 (60.3) | 18 (46.2) | 19 (65.5) | 3 (100.0) |
| >6 | 17 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Age at Bayley-III screening test (days) | 366.62 (6.56) | 366.30 (6.67) | 366.90 (6.99) | 361.33 (0.58) |

TSH, thyroid stimulation hormone; FT4, free thyroxine; ET, euthyroidism; SCH, subclinical hypothyroidism; OH, overt hypothyroidism; IH, isolated hypothyroxinemia; BMI, body mass index. Continuous variables are expressed as mean (SD) or median (IQR), whereas categorical variables are expressed as percentages. *p-value <0.05; **p-value <0.01. *Diabetes includes chronic and gestational diabetes mellitus; hypertension includes chronic and pregnancy-induced hypertension.
Compared to euthyroid women (ET group), the SCH group was more likely to have consumed alcohol during pregnancy, and the IH group was more likely to have higher childbearing age, higher pre-pregnancy BMI, and lower educational levels (Table 1). Comparisons of the characteristics of the mother–infant pairs grouped by neurodevelopment assessment data availability according to different groups showed no differences between participants and non-participants. However, the ET group of mother–infant pairs with available neurodevelopment data had higher mean pre-pregnancy BMI, and the SCH group of mother–infant pairs had lower FT4 concentration (Table S1).

Multivariate linear regression models showed that maternal SCH during pregnancy was associated with decreased receptive communication scores at 1 year of age ($\beta = -0.68$, $p = 0.034$). Infants exposed to maternal IH had decreased gross motor scores ($\beta = -0.83$, $p = 0.008$), while no significant difference was observed in infants of mothers with OH, which may be attributed to the small sample size (Table 2). When the 2011 ATA guidelines were used, similar results were obtained, and the infants exposed to maternal OH had lower gross motor scores ($\beta = -1.11$, $p = 0.021$) (Table S2). The stratified analysis results revealed that there was no statistically significant association of Group SCH$^a$-ET$^b$ (TSH 3.0–4.0 mIU/L and normal FT4) with infant neurodevelopment compared to Group ET$^a$-ET$^b$ (TSH 0.2–3.0 mIU/L and normal FT4), but Group SCH$^a$-SCH$^b$ (TSH >4.0 mIU/L and normal FT4) showed decreased receptive communication scores ($\beta = -0.73$, $p = 0.025$). Group IH$^a$-IH$^b$ (TSH 0.2–3.0 mIU/L and FT4 < 10.55 pmol/L) was associated with lower gross motor scores, but there was no significance after adjustment for potential confounders. However, Group OH$^a$-IH$^b$ (TSH 3.0–4.0 mIU/L and FT4 < 10.55 pmol/L) had lower gross motor scores ($\beta = -1.19$, $p = 0.032$) (Table 3). In the sensitivity analyses, we repeated our main analysis restricting to infants born at full term (37 weeks or greater) or in women without diseases during pregnancy, and the results were not significantly altered (Tables S3, S4).

**DISCUSSION**

In this population-based prospective cohort study, we observed impaired neurodevelopment in infants prenatally exposed to maternal mild hypothyroidism. Interestingly, associations differed in magnitude by subtype of maternal mild hypothyroidism and domains of infant neurodevelopment. Infants of women with maternal SCH were associated with decreased receptive communication only with maternal TSH levels greater than 4.0 mIU/L. For gross motor ability, maternal IH was predominant, and the effect was mainly attributed to mothers with high-normal TSH levels (3.0–4.0 mIU/L). To the best of our knowledge, this is the first study to evaluate the association of maternal mild hypothyroidism with offspring neurodevelopment as stratified by maternal TSH concentration.

Our findings in this prospective cohort study agreed with previous results (13, 14). A retrospective study from China has demonstrated that the offspring of women with SCH (TSH > 4.21 mIU/L) tend to have lower mental development index (MDI) and psychomotor development index (PDI) scores (14). Similarly, a meta-analysis of 39 original articles, including 909,176 individuals, has shown that maternal SCH has distinctly higher risk of intellectual disability in offspring (36).
In contrast, a retrospective study of the Danish National Birth Cohort has indicated no adverse association between SCH (TSH beyond 2.5 mIU/L), and offspring verbal IQ was found (10, 16). These findings indicate that the different TSH cutoff values may be important confounders in various studies, thereby underlining the importance of performing in-depth analyses of observed associations.

Our study identified a significant association between maternal SCH (TSH > 4.0 mIU/L) and decreased receptive communication score in infants, while no significance was observed when maternal TSH levels were greater than 3.0 mIU/L but within the normal range (TSH < 4.0 mIU/L). These findings confirmed that the use of 4.0 mIU/L as the cutoff for TSH avoids the potential risk of overdiagnosis in women with SCH, thereby strengthening the association between SCH during pregnancy and adverse neurodevelopment, mainly when the TSH level is greater than 4.0 mIU/L. In summary, our results further validated and enhanced the current body of evidence suggesting that SCH diagnosed by the ATA 2017 standards is appropriate for screening high-risk women.

We also observed that maternal IH was associated with lower gross motor score in infants. Because maternal OH increases the risk of motor neurodevelopmental delay (37), most studies have shown that IH during early pregnancy is associated with an increased risk of a delay in infant motor development (10, 38). Furthermore, findings from animal studies support the observed associations. Animal studies have demonstrated that the primary brain region affected by decreased availability of maternal FT4 includes the cerebellum, which plays a critical role in motor coordination and motor activity (39). However, the present study is the first to elucidate the association of high-normal TSH levels with offspring neurodevelopment. In the present study, maternal IH with TSH levels between 3.0 and 4.0 mIU/L resulted in significantly decreased gross motor scores in infants compared to infants of mothers with TSH levels lower than 3.0 mIU/L (1.19 vs. 0.70).

Clinical guidelines clearly indicate that OH in pregnant women should be treated (18). Although the above studies have reported adverse outcomes in children born to mothers with IH, no interventional data have yet been published demonstrating the beneficial effects of levothyroxine (LT4) therapy (17, 40). Additionally, a recent guideline from the American College of Obstetrics and Gynecology (ACOG) provides a more conservative approach, essentially advocating treatment only for OH (41). In the present study, among 29 women identified as IH, 9 of them were originally diagnosed as OH according to the ATA 2017 guidelines, indicating that they were previously advised to be treated but later were not. Therefore, these women deserve more attention considering the worse effects on neurodevelopment compared to those with TSH levels below 3.0 mIU/L. Additionally, the lack of treatment effects in large randomized clinical trials (RCTs) should be reviewed. Current RCTs lack stratification of TSH concentration, which may indicate that the treatment effect on the low-risk group (e.g., TSH < 2.5 or 3.0 mIU/L) is diluted, leading to the conclusion of no benefit of treatment. Therefore,
TABLE 3 | Multivariable regression analysis to demonstrate the association of maternal TSH with infant Bayley-III scores.

| Scores | N | Mean (SD) | Model 1 | | Model 2 | |
|---|---|---|---|---|---|---|
| | | | \( \beta \) (95% CI) | p | \( \beta \) (95% CI) | p |
| Cognition | | | | | | |
| ETa-ETb | 596 | 15.77 (2.10) | Ref | | Ref | |
| SCHa-ETb | 106 | 15.82 (2.02) | 0.05 (0.38, 0.47) | 0.827 | 0.06 (0.36, 0.48) | 0.786 |
| SCHa-SCHb | 39 | 15.74 (1.29) | -0.03 (-0.69, 0.63) | 0.930 | -0.08 (-0.76, 0.58) | 0.810 |
| IH-IFb | 20 | 15.30 (1.66) | -0.47 (-1.39, 0.44) | 0.309 | -0.35 (-1.27, 0.57) | 0.456 |
| OHz-IFb | 9 | 14.44 (2.55) | -1.33 (-2.68, 0.02) | 0.054 | -1.32 (-2.69, 0.05) | 0.060 |
| OH-OHb | 3 | 16.33 (0.58) | 0.56 (-1.76, 2.88) | 0.637 | 0.51 (-1.82, 2.84) | 0.668 |
| Receptive communication | | | | | | |
| ETa-ETb | 596 | 11.39 (1.98) | Ref | | Ref | |
| SCHa-ETb | 106 | 11.09 (2.14) | -0.29 (-0.70, 0.11) | 0.157 | -0.29 (-0.70, 0.11) | 0.154 |
| SCHa-SCHb | 39 | 10.74 (1.09) | -0.64 (-1.28, -0.01) | 0.047* | -0.73 (-1.36, -0.09) | 0.025* |
| IH-IFb | 20 | 10.85 (1.57) | -0.54 (-1.41, 0.33) | 0.228 | -0.43 (-1.31, 0.44) | 0.335 |
| OHz-IFb | 9 | 10.78 (1.39) | -0.61 (-1.89, 0.68) | 0.354 | -0.32 (-1.62, 0.98) | 0.631 |
| OH-OHb | 3 | 9.67 (1.53) | -1.72 (-3.94, 0.50) | 0.129 | -1.64 (-3.86, 0.57) | 0.147 |
| Expressive communication | | | | | | |
| ETa-ETb | 596 | 12.09 (2.14) | Ref | | Ref | |
| SCHa-ETb | 106 | 12.07 (2.10) | -0.03 (-0.46, 0.41) | 0.906 | -0.03 (-0.47, 0.40) | 0.883 |
| SCHa-SCHb | 39 | 12.21 (1.98) | 0.11 (-0.57, 0.80) | 0.747 | 0.11 (-0.58, 0.80) | 0.757 |
| IH-IFb | 20 | 12.30 (1.78) | 0.21 (-0.74, 1.15) | 0.666 | 0.35 (-0.60, 1.29) | 0.476 |
| OHz-IFb | 9 | 11.22 (2.22) | -0.87 (-2.26, 0.52) | 0.222 | -0.73 (-2.14, 0.69) | 0.314 |
| OH-OHb | 3 | 12.33 (2.08) | 0.24 (-2.16, 2.64) | 0.844 | 0.4 (-2.01, 2.80) | 0.746 |
| Fine motor | | | | | | |
| ETa-ETb | 596 | 13.09 (1.53) | Ref | | Ref | |
| SCHa-ETb | 106 | 13.25 (1.62) | 0.16 (-0.16, 0.48) | 0.332 | 0.16 (-0.15, 0.48) | 0.315 |
| SCHa-SCHb | 39 | 13.31 (1.56) | 0.22 (-0.28, 0.72) | 0.388 | 0.15 (-0.35, 0.65) | 0.549 |
| IH-IFb | 20 | 13.15 (1.79) | 0.06 (-0.63, 0.75) | 0.858 | 0.23 (-0.46, 0.92) | 0.509 |
| OHz-IFb | 9 | 12.22 (0.83) | -0.87 (-1.88, 0.15) | 0.096 | -0.74 (-1.77, 0.28) | 0.156 |
| OH-OHb | 3 | 13.00 (1.03) | -0.09 (-1.84, 1.66) | 0.922 | 0.03 (-1.72, 1.77) | 0.977 |
| Gross motor | | | | | | |
| ETa-ETb | 596 | 14.58 (1.58) | Ref | | Ref | |
| SCHa-ETb | 106 | 14.45 (1.85) | -0.13 (-0.47, 0.21) | 0.450 | -0.12 (-0.46, 0.21) | 0.467 |
| SCHa-SCHb | 39 | 14.62 (1.68) | 0.03 (-0.48, 0.56) | 0.902 | -0.01 (-0.54, 0.52) | 0.969 |
| IH-IFb | 20 | 13.80 (1.47) | -0.78 (-1.51, 0.00) | 0.025* | -0.70 (-1.43, 0.03) | 0.081 |
| OHz-IFb | 9 | 13.33 (1.32) | -1.25 (-2.32, -0.18) | 0.022* | -1.19 (-2.28, -0.10) | 0.032* |
| OH-OHb | 3 | 13.67 (2.89) | -0.92 (-2.76, 0.93) | 0.331 | -0.89 (-2.73, 0.96) | 0.348 |

Model 1: crude. Model 2: adjusted for childbearing age, pre-pregnancy BMI, parity, mode of conception, maternal education, and sex of infants. CI, confidence interval; ET, euthyroidism; SCH, subclinical hypothyroidism; ORh, overt hypothyroidism; IHr, isolated hypothyroxinemia. * TSH thresholds at 3.0 mIU/L (2011 ATA guidelines). † TSH thresholds at 4.0 mIU/L (2017 ATA guidelines). *p value <0.05.

Further studies should be conducted to identify the optimal treatment threshold of TSH where the benefits of LT4 administration outweigh the risks.

The strengths of the present study included its population-based prospective design, the long follow-up period, and our findings were obtained from TPOAb-negative pregnant women. We observed that maternal SCH was associated with detrimental neurodevelopment of infants, even in women with negative tests for TPOAb, which provided robust evidence to support LT4 treatment of pregnant women with TSH levels ranging from 4.0 to 10.0 mIU/L independent of their thyroid autoantibody status (42). Although the Bayley-III screening test is a validated instrument, it is not a diagnostic tool, and relying on one informant for assessment of neurodevelopment is a major limitation. We did not collect data for thyroid hormone parameters of the offspring after birth, but studies have shown that maternal thyroid function with child neurodevelopment is not mediated or modified by differences in postnatal child thyroid function (43). In addition, the present study was conducted in a single center and had a small sample size. Therefore, our conclusion needs to be further confirmed by multicenter studies with large sample sizes.

CONCLUSIONS

In summary, the present study demonstrated that maternal SCH is associated with decreased receptive communication scores in infants at 1 year of age. In addition, maternal TSH concentrations greater than 4.0 mIU/L and maternal IH are associated with impaired gross motor ability, especially in women with high-normal TSH concentrations (3.0–4.0 mIU/L). In addition, these findings suggest that clinicians should actively determine the primary cause of the decline in FT4 concentration for pregnant women in the higher end of the normal range (3.0–4.0 mIU/L) of TSH and low concentrations of FT4. Further studies are required to identify specific subgroups of women who may benefit from LT4 treatment.
DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

This study was approved by the institutional review board of Nanjing Medical University, China NJMUIRB (2017) 002. Written informed consent was obtained from all the participants or the infants’ parents or guardians.

AUTHOR CONTRIBUTIONS

QW, YJ, and HL drafted the manuscript, analyzed the data, and interpreted the data. QW, TJ, and GZ designed the study, supervised the study, and critically revised the manuscript. All authors contributed to data collection, critically reviewed the article, and approved the final version to be published.

REFERENCES

1. De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, et al. Management of Thyroid Dysfunction During Pregnancy and Postpartum: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2012) 97(8):2543–65. doi: 10.1210/jc.2011-2803
2. Stagnaro-Green A, Abalovich M, Alexander E, Aziari F, Mistman J, Negro R, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid (2011) 21(10):1081–125. doi: 10.1089/thy.2011.0087
3. Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. 2014 European Thyroid Association Guidelines for the Management of Subclinical Hypothyroidism in Pregnancy and in Children. Eur Thyroid J (2014) 3(2):76–94. doi: 10.1159/000362597
4. Bernal J, Guadalupe-Ferraz A, Morte B. Perspectives in the Study of Thyroid Hormone Action on Brain Development and Function. Thyroid (2003) 13(11):1005–12. doi: 10.1089/105072503770867174
5. Porterfield SP, Hendrich CE. The Role of Thyroid Hormones in Prenatal and Neonatal Neurological Development—Current Perspectives. Endocr Rev (1993) 14(1):94–106. doi: 10.1207/s15320007er1401-9
6. Korevaar TIM, Medici M, Visser TP, Peeters RP. Thyroid Disease in Pregnancy: New Insights in Diagnosis and Clinical Management. Nat Rev Endocrinol (2017) 13(10):610–22. doi: 10.1038/nrendo.2017.93
7. Lavado-Autric R, Auso E, Garcia-Velasco JV, Arufe Mdel C, Escobar del Rey F, Berbel P, et al. Early Maternal Hypothyroxinemia Alters Histogenesis and Cerebral Cortex Cytoarchitecture of the Progeny. J Clin Invest (2003) 111(7):1073–82. doi: 10.1172/jci16262
8. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, et al. Maternal Thyroid Deficiency During Pregnancy and Subsequent Neuropsychological Development of the Child. N Engl J Med (1999) 341(8):549–55. doi: 10.1056/nejm199908193410801
9. Henrichs J, Ghassabian A, Peeters RP, Tiemeier H. Maternal Hypothyroxinemia and Effects on Cognitive Functioning in Childhood: How and Why? Clin Endocrinol (Oxf) (2013) 79(2):152–62. doi: 10.1111/ cem.12227
10. Kampouri M, Margetaki K, Koutra K, Kyrklaki A, Karakosta P, Anousaki D, et al. Maternal Mild Thyroid Dysfunction and Offspring Cognitive and Motor Development From Infancy to Childhood: The Rhea Mother-Child Cohort Study in Crete, Greece. J Epidemiol Community Health (2021) 75(1):29–35. doi: 10.1136/jech-2019-213309
11. Pop VI, Kuijpers JL, van Baar AL, Verkerk G, van Son MM, de Vlijder JJ, et al. Low Maternal Free Thyroxine Concentrations During Early Pregnancy are Associated With Impaired Psychomotor Development in Infancy. Clin Endocrinol (Oxf) (1999) 50(2):149–55. doi: 10.1046/j.1365-2265.1999.00639.x
12. Juvela J, Alvarez-Pedrerol M, Rebagliato M, Murcia M, Forns J, Garcia-Esteban R, et al. Thyroxine Levels During Pregnancy in Healthy Women and Early Child Neurodevelopment. Epidemiology (2013) 24(1):150–7. doi: 10.1097/EDE.0b013e318276cd3
13. Su PY, Huang K, Hao JH, Xu YQ, Yan SQ, Li T, et al. Maternal Thyroid Function in the First Twenty Weeks of Pregnancy and Subsequent Fetal and Infant Development: A Prospective Population-Based Cohort Study in China. J Clin Endocrinol Metab (2011) 96(10):3234–41. doi: 10.1210/jc.2011-0274
14. Li Y, Shan Z, Teng W, Xu X, Li Y, Fan C, et al. Abnormalities of Maternal Thyroid Function During Pregnancy Affect Neurodevelopmental Development of Their Children at 25-30 Months. Clin Endocrinol (Oxf) (2010) 72(6):825–9. doi: 10.1111/j.1365-2265.2009.03743.x
15. Murcia M, Rebagliato M, Iñiguez C, Lopez-Espinosa MJ, Estarlich M, Plaza B, et al. Effect of Iodine Supplementation During Pregnancy on Infant Neurodevelopment at 1 Year of Age. Am J Epidemiol (2011) 173(7):804–12. doi: 10.1093/aje/kwq424
16. Andersen SL, Andersen S, Liew Z, Vestergaard P, Olsen J. Maternal Thyroid Function in Early Pregnancy and Neurodevelopmental Performance of the Child at 3 Years of Age. J Clin Endocrinol Metab (2018) 103(4):660–70. doi: 10.1210/jc.2017-02171
17. Lazarus JF, Bestwick JP, Channon S, Paradies R, Maina A, Rees R, et al. Antenatal Thyroid Screening and Childhood Cognitive Function. N Engl J Med (2012) 366(6):493–501. doi: 10.1056/NEJMoa1106104
18. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dossi C, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid (2017) 27(3):315–89. doi: 10.1089/thy.2016.0457
19. Li C, Shan Z, Mao J, Wang W, Xie X, Zhou W, et al. Assessment of Thyroid Function During First-Trimester Pregnancy: What is the Rational Upper Limit of Serum TSH During the First Trimester in Chinese Pregnant Women? J Clin Endocrinol Metab (2014) 99(1):73–9. doi: 10.1210/jc.2013-1674
20. Medici M, Korevaar TIM, Visser WE, Visser TJ, Peeters RP. Thyroid Function in Pregnancy: What is Normal? Clin Chem (2015) 61(5):704–13. doi: 10.1373/ clinchem.2014.236646

FUNDING

This study was funded by the National Natural Science Foundation of China (81803305 and 82103854), the National Science Foundation of Jiangsu Province (BK20180683), and the Maternal and Child Health Association of Jiangsu Province (FYX202031).

ACKNOWLEDGMENTS

We thank all the participants, staff, survey team members, and management team members for their support.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.884851/full#supplementary-material
21. Wiles KS, Jarvis S, Nelson-Piercy C. Are We Overtreating Subclinical Hypothyroidism in Pregnancy? Brmj (2015) 351:h4726. doi: 10.1136/ intj-2014-001244.

22. Korevaar TJ, Medici M, Peeters RP. Subclinical Hypothyroidism Overdiagnosis in Pregnant Women. JAMA Intern Med (2015) 175 (11):1872–3. doi: 10.1001/jamainternmed.2015.5550.

23. Lv H, Diao F, Du J, Chen T, Meng Q, Ling X, et al. Assisted Reproductive Technology and Birth Defects in a Chinese Birth Cohort Study. Lancet Regional Health - Western Pacific (2021) 7:10090. doi: 10.1016/j.lanwpc.2020.10090.

24. Baloch Z, Corayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al. Laboratory Medicine Practice Guidelines. Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease. Thyroid (2003) 13(1):3–126. doi: 10.1089/105072503321086962.

25. Bayley N. Bayley Scales of Infant and Toddler Development, Third Edition: Screening Test Manual. San Antonio: Pearson Clinical Assessment PsychCorp (2006).

26. Veldkamp SAM, Zondervan-Zwijnenburg MAJ, van Bergen E, Barzeva SA, Bayley S, de Jong-van den Berg P, van Elst A, et al. Pregnancy and Perinatal Outcomes in Women with Hypothyroidism and Their Offspring: Results from the Subclinical Thyroid Project. PLoS One (2012) 7(3):e35083. doi: 10.1371/journal.pone.035083.

27. Huang L, Yu X, Keim S, Li L, Zhang L, Zhang J. Maternal Prepregnancy Obesity and Child Neurodevelopmental Outcomes. Int J Epidemiol (2014) 43(3):785–92. doi: 10.1093/ije/dyu830.

28. Kotylewicz B, Perez-Escamilla R, Garmyn MB, Buccini G. Socio-Demographic, Maternal, and Infant CharacteristicsAssociated With Early Childhood Development Delays Among Children of Young Mothers in Brasilia, Brazil. PLoS One (2022) 17(3):e0266018. doi: 10.1371/journal.pone.0266018.

29. Kato T, Nishimura T, Takahashi N, Harada T, Okumura A, Iwabuchi T, et al. Identification of Neurodevelopmental Transition Patterns From Infancy to Early Childhood and Risk Factors Predicting Descending Transition. Sci Rep (2022) 12(1):4822. doi: 10.1038/s41598-022-08827-4.

30. Boto ML, Eichacher E, Ahumada-Drogue E, Nakaki A, Crovetti F, Ciocco MS, et al. Fetal Neurosonography and Infant Neurobehavior in Assisted Reproductive Technologies Following Fresh and Frozen Embryo Transfer. Ultrasound Obstet Gynecol (2021) 57(5):621–3. doi: 10.1542/uog.2021-03.

31. Zou K, Ren J, Luo S, Zhang J, Zhou C, Tan C, et al. Intratransuterine Hyperglycemia Impairs Memory Across Two Generations. Transl Psychiatry (2021) 11(1):434. doi: 10.1038/s41398-021-01556-7.

32. Maher GM, O’Keefe GW, Kearney PM, Kenny LC, Dinan TG, Mattsson M, et al. Association of Hypertensive Disorders of Pregnancy With Risk of Neurodevelopmental Disorders in Offspring: A Systematic Review and Meta-Analysis. JAMA Psychiatry (2018) 75(8):809–19. doi: 10.1001/jamapsychiatry.2018.0854.

33. McCarren CM, Wallace IF, Divon M, Vaughan HG Jr. Cognitive and Neurologic Development of the Premature. Small for Gestational Age Infant Through Age 6: Comparison by Birth Weight and Gestational Age. Pediatrics (1996) 98(6 Pt 1):1167–78. doi: 10.1542/peds.98.6.1167.

34. Breach MR, Lenz KM. Sex Differences in Neurodevelopmental Disorders: A Key Role for the Immune System. Curr Top Behav Neurosci (2022). doi: 10.1007/7854_2022_308.

35. Lipsyk AM, Greenland S. Causal Directed Acyclic Graphs. JAMA (2022) 327(11):1083–4. doi: 10.1001/jama.2022.1816.

36. Thyroid Disease in Pregnancy: ACOG Practice Bulletin, Number 223. JAMA (2017) 318(24):2521–9. doi: 10.1001/jama.2017.18726.

37. Shan ZY, Chen YY, Teng WP, Yu XH, Li CY, Zhou WW, et al. A Study for Maternal Thyroid Hormone Deficiency During the First Half of Pregnancy in China. Eur J Clin Invest (2009) 39(1):37–42. doi: 10.1111/j.1365-2362.2008.02055.x.

38. Craig WV, Allan WC, Pulkkinen AJ, Waisbren S, Spratt DI, et al. Mid-Gestational Maternal Free Thyroxine Concentration and Offspring Neurocognitive Development at Age Two Years. J Clin Endocrinol Metab (2012) 97(1):E22–8. doi: 10.1210/jc.2011-1772.

39. Min H, Dong J, Wang Y, Wang Y, Teng W, Xi Q, et al. Maternal Hypothyroxinemia-Induced Neurodevelopmental Impairments in the Prenygeny. Mol Neurobiol (2016) 53(suppl1):S163–4. doi: 10.1007/s12051-015-9101-x.

40. Casey BM, Thom EA, Peaceman AM, Varner MW, Sorokin Y, Hirtz DG, et al. Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. N Engl J Med (2017) 376(9):815–5. doi: 10.1056/NEJMo1606205.

41. Thyroid Disease in Pregnancy: ACOG Practice Bulletin, Number 223. Obstet Gynecol (2020) 135(6):e261–e74. doi: 10.1097/AOG.0000000000003893.

42. Rotondi M, Chiovato L, Pacini F, Bartalena L, Vitti P. Management of Subclinical Hypothyroidism in Pregnancy: A Comment From the Italian Society of Endocrinology and the Italian Thyroid Association to the 2017 American Thyroid Association Guidelines. “The Italian Way”. Thyroid (2018) 28(5):551–5. doi: 10.1089/thy.2017.0424.

43. Hales C, Taylor PN, Channon S, Paradise R, McEwan K, Zhang L, et al. Controlled Antenatal Thyroid Screening II: Effect of Treating Maternal Suboptimal Thyroid Function on Child Cognition. J Clin Endocrinol Metab (2018) 103(4):1583–91. doi: 10.1210/jc.2017-03738.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Jiang, Lv, Lu, Tao, Qin, Huang, Liu, Xu, Li, Li, Du, Lin, Ma, Chi, Hu, Jiang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.